Article Abstract

PTK2/FAK: a new predictive biomarker for response to radiotherapy in head and neck squamous cell carcinoma

Authors: Emma J. de Ruiter, Stefan M. Willems


With over 600,000 new cases per year worldwide, head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy in developed countries (1). However, despite numerous developments in treatment modalities, the disease-free and overall survival of head and neck cancer patients barely improved over the last decades (2). Radiotherapy plays an indispensable role in the treatment of HNSCC, but mortality among patients because of locoregional failure remains high (3). Therefore, the identification of molecular pathways, involved in resistance to radiation as well as the development of agents enhancing the radiosensitivity of tumor cells, deserves great attention.


  • There are currently no refbacks.

Article Options

Download Citation